Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
ClinicalTrials.gov study NCT04439136. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
ClinicalTrials.gov study NCT06819007. IPD Sharing: YES. Countries: 20. Publications: 0.
TRUDI: TDXD+Durva in HER2+/Low IBC
ClinicalTrials.gov study NCT05795101. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Es
ClinicalTrials.gov study NCT01450696. IPD Sharing: Not stated. Countries: 25. Publications: 0.
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
ClinicalTrials.gov study NCT05892068. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan
ClinicalTrials.gov study NCT06925113. IPD Sharing: YES. Countries: 1. Publications: 0.
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
ClinicalTrials.gov study NCT03412383. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
ClinicalTrials.gov study NCT03125200. IPD Sharing: NO. Countries: 2. Publications: 0.
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02521363. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
ClinicalTrials.gov study NCT01572727. IPD Sharing: Not stated. Countries: 22. Publications: 0.
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT04031885. IPD Sharing: YES. Countries: 2. Publications: 0.
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
ClinicalTrials.gov study NCT00911898. IPD Sharing: Not stated. Countries: 1. Publications: 0.
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
ClinicalTrials.gov study NCT04396626. IPD Sharing: NO. Countries: 1. Publications: 0.
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT01093612. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive I
ClinicalTrials.gov study NCT00464646. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
ClinicalTrials.gov study NCT04172597. IPD Sharing: NO. Countries: 1. Publications: 0.
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
ClinicalTrials.gov study NCT03568422. IPD Sharing: NO. Countries: 1. Publications: 0.
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT07400523. IPD Sharing: YES. Countries: 0. Publications: 0.
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
ClinicalTrials.gov study NCT00448279. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
ClinicalTrials.gov study NCT01480674. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.